EUCTR2012-000477-23-IT
Active, not recruiting
Not Applicable
A randomized phase II study of FOLFORI plus or not CETUXIMAB in elderly advanced colorectal cancer patients. - FOCETELD
AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI0 sitesApril 2, 2012
ConditionsElderly mestatic colorectal cancer patients, Wild-type KRAS ,70-80 years of age, ECOG 0-1.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Elderly mestatic colorectal cancer patients, Wild-type KRAS ,70-80 years of age, ECOG 0-1.
- Sponsor
- AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis if hystologically confirmed metastatic Adenocarcinoma of colorectum. Wild\-type KRAS tumors. 70\-80 years of age. ECOG 0\-1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 74
Exclusion Criteria
- •Dependent for daily living activities. Presence of geriatric syndromes. No previous chemotherapy for metastatic disease. Any investigational agents 4 weeks prior to entry.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Evaluation of the efficacy of a combinaison treatment based upon immunotherapy + chemotherapy to treat patient with a stomach cancerAdvanced gastric or gastro-oesophageal junction adenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10042080 Term: Stomach cancer System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10026476 Term: Malignant neoplasm of stomach System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-002014-13-FRFédération Francophone de Cancérologie Digestive94
Completed
Phase 2
Randomized phase II trial of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with KRAS wild metastatic colorectal cancer refractory to oxaliplatin and bevacizumab with exploratory analysis to predict treatment efficacy and prognosisColorectal cancerJPRN-UMIN000005216West Japan Oncology Group200
Active, not recruiting
Phase 1
Comparison of chemotherapy with radiochemotherapy as treatment of patients with locally advanced, primarily inoperable pancreatic carcinomalocally advanced, primarily inoperable pancreatic carcinomaTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-001850-24-ATABCSG (Austrian Breast & Colorectal Cancer Study Group)112
Active, not recruiting
Not Applicable
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-CZPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176
Active, not recruiting
Not Applicable
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-BEPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176